Time of day of neoadjuvant immune checkpoint inhibitor administration is associated with survival but not pathological response in resectable stage III–IV melanoma: A retrospective cohort study
European Journal of Cancer · 2026-07 · 243 · 116833
DOI: 10.1016/j.ejca.2026.116833 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Cancer, 2026-07. Verfasst von Axel Nelson und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, S…. Hauptthemen laut MEDLINE: Melanoma, Immune Checkpoint Inhibitors, Neoadjuvant Therapy, Skin Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Cancer Society, Swedish Research Council, Stiftelsen Jubileumsklinikens Forskningsfond mot Cancer.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden; Department of Oncology, Sahlgrenska University Hospital, Gothen…
- Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden.
- Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden; Theme Cancer, Karolinska University Hospital, Stockholm, Sweden.
- Department of Surgery, Skåne University Hospital, Kristianstad, Sweden; Department of Clinical Sciences, Division of Surgery, Lund University Cancer Center, Lund, Sweden.
- Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden.
- Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Förderung
- Swedish Cancer Society
- Swedish Research Council
- Stiftelsen Jubileumsklinikens Forskningsfond mot Cancer
- Foundation King Gustaf V Jubilee Fund
- Swedish Society for Medical Research
Zitieren
APA
Nelson, A., Alghaib, S., Björkström, K., Isaksson, K., Krabbe, E., Orme, S., Kadefors, M., Wallander, M., Bjursten, S., Ullenhag, G. J., Carneiro, A., Helgadottir, H., Ny, L., & Olofsson Bagge, R. (2026). Time of day of neoadjuvant immune checkpoint inhibitor administration is associated with survival but not pathological response in resectable stage III–IV melanoma: A retrospective cohort study. European Journal of Cancer, 243, 116833. https://doi.org/10.1016/j.ejca.2026.116833
Vancouver
Nelson A, Alghaib S, Björkström K, Isaksson K, Krabbe E, Orme S, et al. Time of day of neoadjuvant immune checkpoint inhibitor administration is associated with survival but not pathological response in resectable stage III–IV melanoma: A retrospective cohort study. European Journal of Cancer. 2026;243:116833. doi:10.1016/j.ejca.2026.116833
BibTeX
@article{Nelson2026,
author = {Nelson, Axel and Alghaib, Safa and Björkström, Karl and Isaksson, Karolin and Krabbe, Ellen and Orme, Sophie and Kadefors, Måns and Wallander, Mikael and Bjursten, Sara and Ullenhag, Gustav J and Carneiro, Ana and Helgadottir, Hildur and Ny, Lars and Olofsson Bagge, Roger},
title = {Time of day of neoadjuvant immune checkpoint inhibitor administration is associated with survival but not pathological response in resectable stage III–IV melanoma: A retrospective cohort study},
journal = {European Journal of Cancer},
year = {2026},
volume = {243},
pages = {116833},
doi = {10.1016/j.ejca.2026.116833}
}
EUVIMED